Indberetning af ledende medarbejderes transaktioner med AGF A/S' aktier
Aarhus, den 16. oktober 2023
NASDAQ OMX Copenhagen A/S
Meddelelse nr. 24/2023
Indberetning af ledende medarbejderes transaktionermed AGF A/S' aktier
I henhold til Markedsmisbrugsforordningen art. 19 oplyser AGF A/S at have modtaget
følgende meddelelse om erhvervelse af AGF A/S-aktier:
| Navn: | Lars Fournais |
| Årsag: | Lars Fournais er bestyrelsesformand i AGF A/S |
| Udsteder: | AGF A/S |
| Fondskode: | DK0010263722 |
| Betegnelse: | B-aktier |
| Transaktion: | Køb |
| Handelsdato: | Afsluttet pr. 12.10.2023 |
| Marked: | NASDAQ OMX Copenhagen A/S |
| Antal: | 18.769 stk. B-aktier |
| Kursværdi: | 11.808,10 DKK |
Med venlig hilsen
AGF A/S
Dan Holt Jessen
Økonomidirektør
Vedhæftede filer
- Selskabsmeddelelse nr 24-2023 Ledende_medarb_transaktioner_og_koeb_af_aktier_LF
- Indberetning af ledende medarbejderes og disses nærtståendes transaktioner_161023
For at se dette indhold fra ml-eu.globenewswire.com, så skal du give din accept på toppen af denne side.
Information om GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Følg pressemeddelelser fra GlobeNewswire by notified
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra GlobeNewswire by notified
Karolinska Development's portfolio company OssDsign expects fourth-quarter revenues to exceed market estimates6.12.2023 12:38:48 CET | Press release
STOCKHOLM, SWEDEN, December 6, 2023. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that the portfolio company OssDsign expects revenues for the fourth quarter of 2023 to exceed market expectations. Preliminary total revenues for the period October - November amount to SEK 25.2 million, mainly attributable to a continued strong market performance of the company's orthobiologic franchise and some extraordinary orders from a large hospital system. According to preliminary and unaudited data, sales of OssDsign Catalyst amounted to SEK 18.8 million during the period of October – November 2023, whereas OssDsign Cranial recorded sales of SEK 6.4 million. A complete financial statement for the fourth quarter will be presented in OssDsign’s year-end report for 2023, to be published on February 6, 2024. "OssDsign continues its strong growth journey, and we are confident that the company's new strategic direction to fully focus the business on its high-margin orthobiologic franchis
Karolinska Developments portföljbolag OssDsign bedömer att intäkterna för fjärde kvartalet kommer att överträffa marknadens förväntningar6.12.2023 12:38:48 CET | Pressemelding
STOCKHOLM, SVERIGE 6 december 2023. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar att portföljbolaget OssDsign bedömer att intäkterna för det fjärde kvartalet 2023 kommer överträffa marknadens förväntningar. De preliminära totala intäkterna för perioden oktober – november uppgår till 25,2 MSEK, främst till följd av en fortsatt stark marknadsutveckling för bolagets ortobiologiprodukter och ett antal större ordrar från ett stort sjukhusnätverk. Enligt preliminära och oreviderade försäljningsdata för perioden oktober – november 2023 uppnåddes intäkter om 18,8 miljoner kronor för OssDsign Catalyst, medan intäkterna för OssDsign Cranial uppgick till 6,4 miljoner kronor. En fullständig finansiell rapport för det fjärde kvartalet kommer att presenteras i OssDsigns bokslutskommuniké för 2023, som publiceras den 6 februari 2024. ”OssDsign fortsätter sin starka tillväxtresa och vi är övertygade om att bolagets nya strategiska inriktning för att fullt fokusera verksamheten på sina o
XPENG G9 Achieves a Five-Star 2023 Safety Rating from Euro NCAP6.12.2023 11:00:00 CET | Press release
The new XPENG G9, now on sale in Europe, received a five-star 2023 safety rating from Euro NCAPThis is XPENG's second five-star safety rating for an international model following the new P7 in October; and its first SUV obtained both Euro NCAP and C-NCAP five-star ratings AMSTERDAM, Dec. 06, 2023 (GLOBE NEWSWIRE) -- XPENG Motors (“XPENG” or the “Company,” NYSE: XPEV and HKEX: 9868), a leading Chinese smart electric vehicle (“Smart EV”) company, today announces that the international model of their flagship electric SUV, XPENG G9, has received a five-star 2023 safety rating from Euro NCAP. Euro NCAP's five-star safety rating system aims to help consumers, their families and businesses compare vehicles more easily and identify the safest choice for their needs. The tests, which replicate real-life road danger scenarios, represent the European gold standard for comprehensive automotive safety testing. The rating recognises the XPENG G9's advanced body structure and comprehensive passive s
AS Tallink Grupp: Managers’ Transactions6.12.2023 11:00:00 CET | Press release
Person subject to the notification requirement Name: AS Infortar Position: Closely associated person (X) Legal person Person Discharging Managerial Responsibilities in Issuer Name: Hanschmidt, Ain Position: Member of the Supervisory Board Name: Pant, Eve Position: Member of the Supervisory Board Issuer: AS Tallink Grupp LEI: 529900QRMWAKKR3L9W75 Notification type: Initial Notification _____________________________________ Transaction date: 04.12.2023 Venue: Nasdaq OMX Tallinn Instrument type: Share ISIN: EE3100004466 Nature of the transaction: Acquisition Transaction details: (1): Volume: 105,178; Unit price: 0.68 EUR Aggregated transactions: (2): Volume: 105,178; Volume weighted average price: 0.68 EUR Anneli Simm Investor Relations Manager AS Tallink Grupp Sadama 5 10111 Tallinn E-mail Anneli.simm@tallink.ee
CDR-Life Announces First Patient Dosed in Phase 1 Study with Boehringer Ingelheim Evaluating Potential Treatment for Geographic Atrophy6.12.2023 11:00:00 CET | Press release
ZÜRICH, Switzerland, Dec. 06, 2023 (GLOBE NEWSWIRE) -- CDR-Life Inc. today announced that the first patient has been dosed in the Phase 1 trial of BI 771716 for the treatment of geographic atrophy (GA). Licensed to Boehringer Ingelheim, BI 771716 is a highly specific antibody fragment of reduced size, enabling an optimized penetration through all retinal layers to the most critical target site driving GA disease pathology. The Phase 1 study (NCT06006585) is evaluating the safety, tolerability and pharmacokinetics of intravitreal single rising doses and multiple doses of BI 771716 as a potential treatment for GA. GA is a chronic and progressive, irreversible retinal disease that occurs in people with late-stage dry age-related macular degeneration (AMD) impacting the ability to see. More than 5 million people worldwide suffer from GA, of which more than 40% are legally blind. GA worsens with age, affecting 1 in 29 people above the age of 75 and 1 in 4 people above 90. Consequently, risi